1.Genetic epidemiological study on single nucleotide polymorphisms associated with hepatocellular carcinoma in patients with chronic HBV infection.
The Korean Journal of Hepatology 2009;15(1):7-14
Hepatocellular carcinoma (HCC) is associated with hepatitis B virus (HBV) as an etiologic agent in 80% of cases, and is the major cause of death among HBV carriers. Family history of HCC is a known risk factor for the development of HCC among chronically HBV infected patients; therefore, genetic factors are likely to modify the risk of HCC. However, the genetic factors that determine progression to HCC remain mostly to be recovered. It is estimated that there are millions of single nucleotide polymorphisms (SNPs) within human genome and they are likely to explain much of the genetic diversity of individuals. In this review, the natural history of HBV infection and host genetic factors related to HCC, study design and target gene selection for the detection of SNPs related to the occurrence of HCC were discussed. Also, several SNPs or haplotypes, which were reportedly associated with increased or reduced risk of HCC occurrence in patients with chronic HBV infection, were reviewed. Especially, recent studies in Korea, one of the HBV endemic areas, were discussed. Screening of these polymorphisms might be useful in clinical practice to stratify the lower or higher risk group for HCC and might modify the design of HCC surveillance programs in patients with chronic HBV infection, if further genetic susceptibilities are identified. The ongoing studies of the distributions and functions of the implicated allele polymorphisms will not only provide insight into the pathogenesis of HCC, but may also provide a novel rationale for new methods of diagnosis and therapeutic strategies.
Biological Markers
;
Carcinoma, Hepatocellular/diagnosis/*epidemiology/*genetics
;
Genetic Predisposition to Disease
;
Hepatitis B, Chronic/*complications/diagnosis/epidemiology
;
Humans
;
Liver Neoplasms/diagnosis/*epidemiology/*genetics
;
*Polymorphism, Single Nucleotide
2.Occult Hepatitis B Virus Infection and Hepatocellular Carcinoma.
The Korean Journal of Gastroenterology 2013;62(3):160-164
Many studies have suggested that occult HBV infection has a substantial clinical relevance to hepatocellular carcinoma (HCC). Occult HBV infection is an important risk factor for the development of cirrhosis and HCC in patients without HBsAg. As a matter of fact, occult HBV infection is one of the most common causes of crytogenic HCC in endemic areas of HBV. However, there still are controversial issues about the association between occult HBV infection and HCC according to the underlying liver disease. In alcoholic cirrhosis, occult HBV infection may exert synergistic effect on the development of HCC. However, there is insufficient evidence to relate occult HBV infection to hepatocarcinogenesis in non-alcoholic fatty liver disease. In cryptogenic HCC, occult HBV infection may play a direct role in the development of HCC. In order to elucidate the assocciation between occult HBV infection and HCC, underlying liver disease must be specified and larger number of cases must be included in future studies.
Carcinoma, Hepatocellular/*complications/*diagnosis/epidemiology
;
DNA, Viral/analysis
;
Hepatitis/complications
;
Hepatitis B/*complications/*diagnosis/epidemiology
;
Hepatitis B virus/genetics
;
Humans
;
Liver Cirrhosis, Alcoholic/complications
;
Liver Neoplasms/*complications/*diagnosis/epidemiology
;
Risk Factors
3.Distribution of HBV genotypes and clinical characteristics of HBV-related hepatocellular carcinoma patients in Deyang District, Sichuan Province.
Jia-hong YANG ; Gao CHEN ; Hao ZHANG ; Xue-bing CHEN ; Xiu WANG ; Wan-rong LUO
Chinese Journal of Hepatology 2013;21(6):473-474
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Carcinoma, Hepatocellular
;
diagnosis
;
epidemiology
;
virology
;
Child
;
China
;
epidemiology
;
Female
;
Genes, Viral
;
Genotype
;
Hepatitis B virus
;
genetics
;
Humans
;
Liver Neoplasms
;
diagnosis
;
epidemiology
;
virology
;
Male
;
Middle Aged
;
Viral Load
;
Young Adult
4.The significance of anti-HBc and occult hepatitis B virus infection in the occurrence of hepatocellular carcinoma in patients with HBsAg and anti-HCV negative alcoholic cirrhosis.
Min Ju KIM ; Oh Sang KWON ; Nak So CHUNG ; Seo Young LEE ; Hyuk Sang JUNG ; Dong Kyun PARK ; Yang Suh KU ; Yu Kyung KIM ; Yun Soo KIM ; Ju Hyun KIM
The Korean Journal of Hepatology 2008;14(1):67-76
BACKGROUND/AIMS: Alcohol and the hepatitis B virus (HBV) exert synergistic effects in hepatocelluar carcinogenesis. We aimed to elucidate the clinical significance of the antibody to hepatitis B core antigen (anti-HBc) and occult HBV infection on the development of hepatocellular carcinoma (HCC) in patients with alcoholic liver cirrhosis (LC). METHODS: Patients with alcoholic LC alone (n=193) or combined with HCC (n=36), who did not have HBsAg or antibody to hepatitis C virus were enrolled. Clinical data and laboratory data including anti-HBc were investigated at enrollment. The polymerase chain reaction was applied to HBV DNA using sera of patients with HCC or LC after age and sex matching. RESULTS: Patients with HCC were older (60+/-11 years vs. 53+/-10 years, mean+/-SD, P<0.001), more likely to be male (100% vs. 89%, P=0.03), and had a higher positive rate of anti-HBc (91.2% vs. 77.3%, P=0.067), and a higher alcohol intake (739+/-448 kg vs. 603+/-409 kg, P=0.076) than those with LC. Age was the only significant risk factor for HCC revealed by multiple logistic regression analysis (odds ratio, 1.056; P=0.003). The positive rate of anti-HBc and alcohol intake did not differ in age- and sex-matched subjects between the LC (n=32) and HCC (n=31) groups. However, the detection rate of serum HBV DNA was higher in the HCC group (48.4%) than in the LC group (0%, P<0.001). CONCLUSIONS: Anti-HBc positivity is not a risk factor for HCC. However, occult HBV infection may be a risk factor for HCC in patients with alcoholic LC.
Adult
;
Aged
;
Antibodies, Viral/blood
;
Carcinoma, Hepatocellular/diagnosis/epidemiology/*etiology
;
DNA, Viral/analysis
;
Female
;
Hepatitis B/*complications/diagnosis
;
Hepatitis B Core Antigens/*immunology
;
Hepatitis B Surface Antigens/immunology
;
Hepatitis B virus/genetics/immunology/isolation & purification
;
Hepatitis C/complications/diagnosis
;
Humans
;
Liver Cirrhosis, Alcoholic/*complications/diagnosis/epidemiology
;
Liver Neoplasms/diagnosis/epidemiology/*etiology
;
Male
;
Middle Aged
;
Risk Factors
5.Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients.
Jeong Han KIM ; Soon Young KO ; Won Hyeok CHOE ; So Young KWON ; Chang Hong LEE
Clinical and Molecular Hepatology 2013;19(3):273-279
BACKGROUND/AIMS: Lamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB). The aim of this study was to determine the efficacy of this combination therapy in hepatocellular carcinoma (HCC) patients. METHODS: The medical records of CHB patients who developed LAM resistance and were treated with LAM plus ADV combination therapy for more than 6 months were reviewed. Their virological response (VR; undetectable HBV DNA) and biochemical response (BR; alanine aminotransferase normalization) were evaluated, and the findings of HCC and non-HCC patients were compared. RESULTS: The data from 104 patients (19 with HCC and 85 without HCC) were analyzed. The VR rates did not differ significantly between the HCC and non-HCC groups: 33.3% vs. 55.6% at 12 months (P=0.119), 58.3% vs. 67.2% at 24 months (P=0.742), 50% vs. 69.8% at 36 months (P=0.280), and 66.7% vs. 71.0% at 48 months (P=1.000). The BR rates also did not differ significantly between the groups: 55.6% vs. 84.0% at 12 months (P=0.021), 58.3% vs. 83.8% at 24 months (P=0.057), 70.0% vs. 77.8% at 36 months (P=0.687), and 66.7% vs. 80.6% at 48 months (P=0.591). CONCLUSIONS: The efficacy of LAM plus ADV combination therapy is comparable in HCC and non-HCC patients.
Adenine/*analogs & derivatives/therapeutic use
;
Adult
;
Antiviral Agents/*therapeutic use
;
Carcinoma, Hepatocellular/*diagnosis/epidemiology/etiology
;
DNA, Viral/analysis
;
Drug Administration Schedule
;
Drug Resistance, Viral
;
Drug Therapy, Combination
;
Genotype
;
Hepatitis B virus/genetics
;
Hepatitis B, Chronic/*drug therapy/virology
;
Humans
;
Incidence
;
Lamivudine/*therapeutic use
;
Liver Cirrhosis/diagnosis/epidemiology/etiology
;
Liver Neoplasms/*diagnosis/epidemiology/etiology
;
Middle Aged
;
Organophosphonates/*therapeutic use
;
Retrospective Studies
;
Treatment Outcome